U.S. Tardive Dyskinesia Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug (Deutetrabenazine, Valbenazine, and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Country Forecast, 2023-2030

The U.S. tardive dyskinesia therapeutics market size was worth USD 2.24 billion in 2022 and is projected to grow at a CAGR of 7.8% during the forecast period. 

The U.S. has witnessed a substantial increase in awareness of Tardive Dyskinesia (TD) among the patient population. The ailment is a type of movement disorder that occurs as a side effect of the long term use of antipsychotics. In May 2022, the Gerontological Advanced Practice Nurses Association (GAPNA) organized the tardive dyskinesia therapeutics awareness program from 1^st May – 7^th May. Since 2018, the program is conducted every year in collaboration with Neurocrine Biosciences in all the 50 states in the U.S.

The prevalence of this disease is rising due to the usage of antipsychotic drugs in treating schizophrenia, schizoaffective disorder, and bipolar disorder. This is propelling the demand for effective tardive dyskinesia therapeutics measures for this condition. The outbreak of COVID-19 led to slower market growth due to a decline in hospital visits for the diagnosis and treatment of this disease.

LATEST TRENDS

Introduction of Innovative Campaigns to Increase Patient Engagement

Many public and private organizations are conducting TD awareness week and introducing software applications to educate people about the symptoms and keep track of these symptoms. For instance, the National Organization for Tardive Dyskinesia (NOTD), a non-profit organization, conducted TD awareness week in 50 states in the U.S. in May 2022. They also launched a smartphone app to track symptoms and chart the progress of any tardive dyskinesia treatment.

DRIVING FACTORS

Increasing Prevalence of Tardive Dyskinesia to Propel Industry Growth

Patients treated for schizophrenia, schizoaffective disorder, bipolar disorder, and other neurological disorders are most likely to develop persistent and irreversible tardive dyskinesia. Moreover, it is not rare, and anyone exposed to treatment with antipsychotic drugs is at risk, which is one of the critical factors responsible for the growing prevalence of this disease. According to an article published by the BMC Psychiatry Journal in 2020, the prevalence of antipsychotic use among U.S. adults was estimated at 1.7%. Increase in consumption of antipsychotic drug will lead to an increase in demand for tardive dyskinesia therapeutics during the forecast period.

RESTRAINING FACTORS

Lack of Drugs Approved for the Treatment May Restrain Market Growth

The disease has no known cure, but its symptoms can be managed. This includes mental and physical changes such as facial grimacing, rocking or thrusting the pelvis, jaw swinging, and repetitive chewing. Physical symptoms typically include twitching, shaking, or jerking in the hands, feet, face, or torso, which may worsen over time.

There are only two approved vmat2 inhibitors class medications for tardive dyskinesia. These are valbenazine (INGREZZA) and deutetrabenazine (AUSTEDO). Thus, the lack of newly approved drugs to treat this condition limits the treatment options for the patient population. This is subsequently limiting the U.S. tardive dyskinesia therapeutics market growth.

The annual cumulative incidence of tardive dyskinesia is about 4% to 5% and the prevalence rate is 20% to 30% globally.

SEGMENTATION

By Drug Analysis

By drug, the market is segmented into deutetrabenazine, valbenazine, and others.

The valbenazine segment dominated the U.S. tardive dyskinesia therapeutics market share in 2022, owing to strategic initiatives made by the market players to drive the adoption of valbenazine in the country.

• According to the 2021 annual report of Neurocrine Biosciences, Inc., the company entered INTO distribution agreements for the INGREZZA (valbenazine) with a limited number of specialty pharmacy providers and distributors, which represented approximately 82.0% of INGREZZA product revenue in 2021.

By Distribution Channel Analysis

Based on distribution channel, the market is segmented into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The hospital pharmacies segment held a larger share in the U.S. market in 2022. The dominance of this segment is attributed to the fact that most medications for treatment can only be prescribed by trained medical professionals at hospitals after a thorough examination. The increase in the number of patients seeking treatment for this condition will escalate the demand for early diagnosis and effective treatment options in hospital settings.

• For instance, as per an article published in the National Alliance on Mental Health (NAMI) in November 2022, Tardive Dyskinesia (TD) affects around 600,000 people in the U.S. However, only 30% of those affected are diagnosed while 70% of individuals potentially living with TD are yet to be diagnosed.

KEY INDUSTRY PLAYERS

In terms of competitive landscape, Neurocrine Biosciences, Inc. dominated the U.S. market in 2022. The company's apex position is due to the strong sales performance of its approved product, INGREZZA (valbenazine). The company is focused on incorporating the Direct-to-Consumer (DTC) model to increase its customer base and expand its product awareness in the U.S. market.

Some other key tardive dyskinesia therapeutics players with a considerable presence in the U.S. include Teva Pharmaceutical Industries Ltd. and Mitsubishi Tanabe Pharma Corporation. These companies are focusing on increasing patient population awareness through innovative campaigns and product launches. For instance, in April 2021, Teva pushed its marketing strategy by introducing its first consumer campaign for AUSTEDO to reach more people with tardive dyskinesia conditions. Such strategic moves are expected to strengthen the companies' presence in the U.S. market.

LIST OF KEY COMPANIES PROFILED:

• Mitsubishi Tanabe Pharma Corporation (Mitsubishi Chemical Group Corporation) (Japan)


• Teva Pharmaceutical Industries Ltd. (Israel)


• Neurocrine Biosciences, Inc. (U.S.)


• SOM BIOTECH (Spain)


• Luye Pharma Group (China)

KEY INDUSTRY DEVELOPMENTS: 

• May 2022 – Neurocrine Biosciences presented findings from a study on using INGREZZA capsules for tardive dyskinesia therapeutics at the American Psychiatric Association (APA). The data showed that taking the medication (40 mg or 80 mg) once a day for 48 weeks led to significant improvements in TD symptoms, as clinicians and patients rated while maintaining stability in psychiatric symptoms.


• August 2021 – Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd., released the results from a posthoc analysis of a three-year study assessing the effectiveness and safety of AUSTEDO (deutetrabenazine) tablets for treating Tardive Dyskinesia (TD) in patients under 55 and over 55.


• August 2021 – Luye Pharma Group announced that the new drug application for LY03015, its vesicular monoamine transporter 2 (VMAT2) inhibitor of next generation, used for the treatment in TD was submitted in the U.S. The Phase I clinical trial is expected to commence in the near future.

REPORT COVERAGE

The market research report provides a detailed analysis of the industry. It focuses on key aspects such as the prevalence of tardive dyskinesia in the U.S. Additionally, it includes an overview of the regulatory and reimbursement scenario for tardive dyskinesia, key industry developments, and the impact of COVID-19 on the market. Besides this, the report offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, it encompasses several factors that have contributed to the growth of the market in recent years.

Report Scope & Segmentation